Point72 Takes 5.0% Stake in Arcutis Biotherapeutics

TL;DR

**Point72 just bought 5% of Arcutis Biotherapeutics, signaling a bullish outlook.**

AI Summary

Point72 Asset Management, L.P., a hedge fund, has disclosed a significant stake in Arcutis Biotherapeutics, Inc., reporting beneficial ownership of 4,836,116 shares of common stock as of January 30, 2024. This represents a 5.0% ownership stake in the pharmaceutical company. This matters to investors because a major institutional investor like Point72 taking a substantial position can signal confidence in Arcutis's future prospects, potentially influencing other investors and the stock price.

Why It Matters

A large institutional investment by Point72 Asset Management could be seen as a vote of confidence in Arcutis Biotherapeutics, potentially attracting more investor interest and positively impacting its stock performance.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, which generally reduces perceived risk by showing external confidence in the company.

Analyst Insight

A smart investor would research Arcutis Biotherapeutics' recent performance and future pipeline, considering that a major hedge fund like Point72 has taken a substantial position, which could indicate a positive outlook.

Key Numbers

• 4,836,116 — Shares Owned (Total shares of Arcutis Biotherapeutics common stock beneficially owned by Point72 Asset Management, L.P.)
• 5.0% — Ownership Percentage (The percentage of Arcutis Biotherapeutics' common stock owned by Point72 Asset Management, L.P.)

Key Players & Entities

• Point72 Asset Management, L.P. (company) — the reporting person, a hedge fund
• Arcutis Biotherapeutics, Inc. (company) — the subject company, a pharmaceutical preparations company
• 4,836,116 (dollar_amount) — number of shares beneficially owned by Point72
• 5.0% (dollar_amount) — percentage of Arcutis Biotherapeutics owned by Point72
• January 30, 2024 (dollar_amount) — date of the event requiring the filing

Forward-Looking Statements

• Arcutis Biotherapeutics' stock price may see increased investor interest due to Point72's significant stake. (Arcutis Biotherapeutics, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• p24-0547sc13g.htm (SC 13G) — 74KB
• p24-0547exhibit99.htm (EX-99.1) — 7KB
• 0000902664-24-000842.txt ( ) — 83KB

(a)

Item 1(a). Name of Issuer. Arcutis Biotherapeutics, Inc. (the " Issuer ").

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Point72 Asset Management, L.P. (" Point72 Asset Management ") with respect to common stock, par value $0.0001 per share (" Shares "), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (" Point72 Associates "); (ii) Point72 Capital Advisors, Inc. (" Point72 Capital Advisors Inc .") with respect to Shares held by Point72 Associates; (iii) Cubist Systematic Strategies, LLC (" Cubist Systematic Strategies ") with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen (" Mr. Cohen ") with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1 , pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

(c)

Item 2(c). Place of Organization. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Mr. Cohen is a United States citizen.

(d)

Item 2(d). Title of Class of Securities. Common Stock, par value $0.0001 per share.

(e)

Item 2(e). CUSIP Number. 03969K108 Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: Not applicable. CUSIP No. 03969K108 13G Page 7 of 8 Pages Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 30, 2024. Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein. Item 5. If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares. Item 7. Identification and Class

View Full Filing

View this SC 13G filing on SEC EDGAR